CFO at Avanos (NYSE: AVNS) awarded new stock options and RSUs

Rhea-AI Filing Summary

Avanos Medical SVP and CFO Scott Michael Galovan received new equity awards. He was granted employee stock options for 69,630 shares of Common Stock at an exercise price of $13.69 per share, expiring on March 13, 2036, bringing his option holdings to 96,212 shares.

He also received 29,481 shares of Common Stock as a grant, increasing his direct share ownership to 139,824 shares. These awards include time-based restricted share units that vest in scheduled installments on March 13, 2027, March 13, 2028 and March 13, 2029, aligning a portion of his compensation with the company’s long-term performance.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Galovan Scott Michael

Role SVP, Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (right to buy)	69,630	$0.00	--
Grant/Award	Common Stock	29,481	$0.00	--

Holdings After Transaction: Employee Stock Option (right to buy) — 96,212 shares (Direct); Common Stock — 139,824 shares (Direct)

Footnotes (1)

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Key Figures

New stock options granted: 69,630 options Option exercise price: $13.69 per share Option expiration: March 13, 2036 +5 more

8 metrics

New stock options granted 69,630 options Employee Stock Option grant on March 13, 2026

Option exercise price $13.69 per share Exercise price for 69,630 newly granted options

Option expiration March 13, 2036 Expiration date of newly granted options

Options held after grant 96,212 options Total options following derivative transaction

New common shares granted 29,481 shares Grant of Common Stock on March 13, 2026

Common shares after grant 139,824 shares Direct Common Stock holdings after transaction

TRSU vesting schedule 1/3 each in 2027, 2028, 2029 Time-based RSUs vest annually starting March 13, 2027

Alternate vesting allocation 30%, 30%, 40% Another award vests across 2027, 2028, 2029

Key Terms

time-based restricted share units, TRSUs, 2021 Long Term Incentive Plan, Employee Stock Option (right to buy), +1 more

5 terms

time-based restricted share units financial

"Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan"

TRSUs financial

"Each TRSU is the economic equivalent of one share of Common Stock"

2021 Long Term Incentive Plan financial

"awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended"

Employee Stock Option (right to buy) financial

"security_title: Employee Stock Option (right to buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Galovan Scott Michael

(Last) (First) (Middle)

5405 WINDWARD PARKWAY

SUITE 100

(Street)

ALPHARETTA GEORGIA 30004

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AVANOS MEDICAL, INC. [ AVNS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/13/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)
04/01/2026

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/13/2026		A		29,481(1)	A	$0	139,824	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$13.69	03/13/2026		A		69,630		(2)	03/13/2036	Common Stock	69,630	$0	96,212	D

Explanation of Responses:

1. Represents time-based restricted share units (TRSUs) awarded pursuant to the Issuer's 2021 Long Term Incentive Plan, as amended. The award will vest 1/3 on March 13, 2027, 1/3 on March 13, 2028 and 1/3 on March 13, 2029. Each TRSU is the economic equivalent of one share of Common Stock.

2. The award will vest 30% on March 13, 2027, 30% on March 13, 2028 and 40% on March 13, 2029.

Remarks:

This Form 4/A is being filed to correct a Form 4/A filed on April 1, 2026 that erroneously added to the number of stock options issued to the Reporting Person on March 13, 2026 pursuant to the Issuer's 2021 Long-Term Incentive Plan, as amended. The number of stock options originally reported in the Form 4 filed on March 17, 2026 was correct.

	/s/ John Hurley, as attorney-in-fact for Scott M. Galovan	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What equity awards did AVNS CFO Scott Michael Galovan receive?

Scott Michael Galovan received stock options and common shares as equity awards. He was granted options for 69,630 shares at $13.69 per share and 29,481 shares of Common Stock, increasing his direct holdings and tying more of his pay to Avanos Medical’s long-term results.

How many Avanos (AVNS) stock options does the CFO hold after this filing?

After the grant, the CFO holds 96,212 stock options. These include 69,630 newly granted options with an exercise price of $13.69 per share, expiring on March 13, 2036, reflecting a significant portion of his compensation linked to future share price performance.

What is the vesting schedule for the AVNS CFO’s time-based restricted share units?

The time-based restricted share units vest over three years. The award will vest one-third on March 13, 2027, one-third on March 13, 2028, and one-third on March 13, 2029, gradually delivering Common Stock as long as employment and plan conditions are met.

How many Avanos (AVNS) common shares does the CFO own after the grant?

Following the grant, the CFO directly owns 139,824 common shares. This reflects the addition of 29,481 newly awarded shares, which include time-based restricted share units that convert into Common Stock over several years as they vest under the company’s long-term incentive plan.

What does each TRSU awarded to the AVNS CFO represent?

Each time-based restricted share unit (TRSU) is economically equal to one AVNS share. As TRSUs vest on scheduled dates, they effectively convert into shares of Common Stock, providing the CFO with stock-based compensation tied directly to Avanos Medical’s share price.

Under which plan were the AVNS CFO’s equity awards granted?

The awards were granted under Avanos Medical’s 2021 Long Term Incentive Plan. The plan, as amended, authorizes time-based restricted share units and stock options, using multi-year vesting schedules to align executive compensation with sustained company performance and shareholder value creation.